Hiểu sao cho đúng về các quan ngại của viên tránh thai nội tiết hằng ngày

Các quan ngại của viên tránh thai nội tiết. Uống thuốc tránh thai nội tiết có gây tăng cân không?
Sử dụng thuốc ngừa thai kéo dài có ảnh hưởng khả năng thụ thai không? Thuốc tránh thai ảnh hưởng đến chu kỳ kinh nguyệt? Thuốc tránh thai ảnh hưởng đời sống tình dục?

Tìm hiểu thêm:


  1. Foidart, J.-M., Wuttke, W., Bouw, G. M., Gerlinger, C., & Heithecker, R. (2000). A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. The European Journal of Contraception & Reproductive Health Care, 5(2), 124–134. doi:10.1080/13625180008500387
  2. Burkman, R., Schlesselman, J. J., & Zieman, M. (2004). Safety concerns and health benefits associated with oral contraception. American Journal of Obstetrics and Gynecology, 190(4), S5–S22.
  3. Casado-Espada, N. M., de Alarcón, R., de la Iglesia-Larrad, J. I., Bote-Bonaechea, B., & Montejo, Á. L. (2019). Hormonal Contraceptives, Female Sexual Dysfunction, and Managing Strategies: A Review. Journal of Clinical Medicine, 8(6), 908. doi:10.3390/jcm8060908
  4. (2005). Noncontraceptive health benefits of combined oral contraception. Human Reproduction Update, 11(5), 513–525. doi:10.1093/humupd/dmi019 
  5. Schindler, A. E. (2012). Non-Contraceptive Benefits of Oral Hormonal Contraceptives. International Journal of Endocrinology and Metabolism, 11(1). doi:10.5812/ijem.4158
  6. Oelkers, W. (1995). Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. Journal of Clinical Endocrinology & Metabolism, 80(6), 1816–1821. doi:10.1210/jc.80.6.1816 
  7. Chumpalova, P., Iakimova, R., Stoimenova-Popova, M., Aptalidis, D., Pandova, M., Stoyanova, M., & Fountoulakis, K. N. (2020). Prevalence and clinical picture of premenstrual syndrome in females from Bulgaria. Annals of General Psychiatry, 19(1). doi:10.1186/s12991-019-0255-1 
  8. Klipping, C., Duijkers, I., Trummer, D., & Marr, J. (2008). Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception, 78(1), 16–25. doi:10.1016/j.contraception.2008.02.019 
  9. Willis, S. A., Kuehl, T. J., Spiekerman, A. M., & Sulak, P. J. (2006). Greater inhibition of the pituitary–ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception, 74(2), 100–103. doi:10.1016/j.contraception.2006.02.006
  10. Beral, V., Doll, R., Hermon, C. (2008). Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. The Lancet, 371(9609), 303–314. doi:10.1016/s0140-6736(08)60167-1 
  11. Tsilidis, K. K., Allen, N. E., Key, T. J., Dossus, L., Lukanova, A., Bakken, K., … Riboli, E. (2011). Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. British Journal of Cancer, 105(9), 1436–1442. doi:10.1038/bjc.2011.371 
  12. WHO : BMJ. 2002 Apr 6; 324(7341): 808.doi: 10.1136/bmj.324.7341.808/a. PMCID: PMC1122763. PMID: 11934771. WHO links long term pill use to cervical cancer Owen Dyer)
  13. Ellen M Mikkelsen , Anders H RiisLauren A WiseElizabeth E HatchKenneth J RothmanHenrik Toft Sorensen.(2013). Pre-gravid oral contraceptive use and time to pregnancy: a Danish prospective cohort study